Glucose B. Braun

Glucose B. Braun is an intravenous solution for injection that contains the active ingredient glucose as its sole carbohydrate component. The product is supplied in a sterile aqueous solution, with the exact concentration not disclosed in the public data. It is classified as an excipient/solvent and is used primarily as a parenteral source of energy. The preparation is marketed in the European Union and requires a prescription.

Glucose B. Braun is indicated for several clinical situations where intravenous carbohydrate delivery is needed.

- Management of hypoglycemia when oral glucose administration is not feasible. - Component of parenteral nutrition regimens to provide caloric support. - Fluid and electrolyte replacement solutions where an energy source is required. - Adjunct therapy during peri‑operative care to maintain blood glucose stability. - Support for patients receiving total parenteral nutrition who need a carbohydrate source.

When administered intravenously, glucose solutions can produce a range of physiological responses, most of which are related to blood sugar fluctuations and infusion tolerance.

Common: - Transient hyperglycemia or mild elevation of blood glucose. - Local irritation or pain at the infusion site. - Nausea or mild gastrointestinal discomfort. - Electrolyte shifts, particularly sodium and potassium changes. - Headache or dizziness related to rapid glucose infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypoglycemia after abrupt discontinuation. - Fluid overload or pulmonary edema in volume‑sensitive patients. - Allergic or anaphylactic reaction to the solution components. - Metabolic acidosis in patients with impaired glucose utilization.

Glucose B. Braun should be used with careful clinical assessment, and several precautions are recommended to minimize risks.

- Verify patient’s blood glucose level before and during infusion. - Adjust infusion rate in patients with renal or cardiac insufficiency. - Monitor fluid balance to avoid overload, especially in critically ill patients. - Use compatible infusion sets and avoid mixing with incompatible drugs. - Consider special dosing in neonates, infants, and patients with impaired glucose metabolism. - Store the solution according to manufacturer guidelines to maintain sterility.

Glucose solutions can interact with other intravenous agents, affecting their efficacy or safety.

Avoid: - Co‑administration with high‑dose insulin without appropriate monitoring. - Simultaneous infusion of potassium chloride in concentrations that may precipitate. - Mixing with calcium‑containing solutions that can cause precipitation.

Use with caution: - Concurrent use of diuretics that may alter electrolyte balance. - Administration alongside beta‑blockers, which can mask hypoglycemia symptoms. - Use with other hyperosmolar solutions that increase risk of fluid overload.